Finally, we found a correlation between ZNF224 mRNA expression levels and responsiveness to imatinib therapy in patients with BCR-ABL positive chronic phase CML (CP-CML). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.